Please login to the form below

Not currently logged in
Email:
Password:

Orkambi

This page shows the latest Orkambi news and features for those working in and with pharma, biotech and healthcare.

Vertex's two-drug cystic fibrosis treatment cleared in US

Vertex's two-drug cystic fibrosis treatment cleared in US

efficacy and is more tolerable than Orkambi, which has respiratory side effects that affect around a quarter of patients and can lead to therapy drop-outs. ... of $100m-$200m this year “based on identified patients who came off Orkambi in the last two

Latest news

  • Vertex’s Orkambi receives EU green light for licence extension Vertex’s Orkambi receives EU green light for licence extension

    Vertex’ s Orkambi receives EU green light for licence extension. Becomes first medicine to treat the underlying cause of CF in children. ... He said: “The innovative long-term agreements we have reached in countries like Ireland will enable eligible

  • Vertex hits sweet spot with triple cystic fibrosis therapy Vertex hits sweet spot with triple cystic fibrosis therapy

    At the moment its two approved therapies - Kalydeco (ivacaftor) and Orkambi (lumacaftor and ivacaftor) - together account for less than half of all CF mutations. ... The improvements are roughly in line with those seen with Kalydeco and Orkambi in

  • Vertex strikes Italian reimbursement deal for Orkambi Vertex strikes Italian reimbursement deal for Orkambi

    Vertex strikes Italian reimbursement deal for Orkambi. AIFA gives the go-ahead for the cystic fibrosis treatment. ... Vertex has struck a market access deal in Italy for its cystic fibrosis treatment Orkambi (lumacaftor/ivacaftor).

  • FDA broadens use of cystic fibrosis drug Kalydeco FDA broadens use of cystic fibrosis drug Kalydeco

    The FDA verdict could also boost Vertex's follow-up CF combination therapy  Orkambi (ivacaftor and lumacaftor), which was launched in 2015 and has already overtaken its predecessor in sales terms,

  • Vertex' cystic fibrosis drug too costly, says NICE Vertex' cystic fibrosis drug too costly, says NICE

    denied with NICE saying this would require Orkambi to be supplied "in a cost-effective way". ... on Orkambi - not reviewed by NICE - suggests Orkambi almost halved the rate of decline in lung function in people with CF over a two-year period.

More from news
Approximately 6 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Vertex’growth has been helped by obtaining reimbursement for its CFTR modulator, Orkambi, in Europe, ”says Pavan Kottamasu, analyst, cardiovascular and metabolic disorders. ... Vertex has two - with Kalydeco sitting alongside Orkambi in an impressive

  • Market access in Europe: balancing access and affordability Market access in Europe: balancing access and affordability

    for Vertex's Orkambi (lumacaftor/ivacaftor), a treatment for cystic fibrosis.

  • Using social data to see patients more clearly Using social data to see patients more clearly

    Last year, while cystic fibrosis treatment Orkambi was in the final stages of development, Treato found that 58% of trial participants who discussed the drug on social media “ reported beneficial effects.” ... This kind of information would have

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Marketing strategy in complex environments

    Marketing strategy in complex environments. Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics